

Corporate Presentation for 2025



KUANGLI BIO-TECH
HOLDINGS

Kuangli Bio-tech Holdings Co., Ltd

Stock Symbol : 6431

Disclaimer



KUANGLI BIO-TECH
HOLDINGS

- The forward-looking information presented in this presentation and related disclosures, including operational outlook, financial condition, and business forecasts, are based on internal data and information derived from the overall economic development situation, as of the time of this disclosure.
- The actual operational results, financial condition, and business performance of the company in the future may differ from the forward-looking information presented. Various factors, including but not limited to changes in market demand, policies and regulations, overall economic conditions, and other risks beyond the company's control, could contribute to such differences.
- The information provided in this presentation reflects the company's views as of the present moment regarding the future. It is neither expressly nor implicitly stated or guaranteed to be accurate, complete, or reliable. The company is not responsible for updating or revising the content of the presentation for any changes or adjustments that may occur in the future.



The content of the briefing

1 Company
Profile

2 Business
in China

3 Business
in Taiwan

4 Financial
Information

5 Q&A



KUANGLI BIO-TECH
HOLDINGS

1. Company Profile

The Chronicle of Kuangli Bio-tech Group



Photoelectric period

Restructuring period

Post-restructuring period

2002
-2013

- Kunshan Kuangli Optoelectronic Technology Co., Ltd. was established in May 2002
- Xinguangtai Optoelectronic Technology Co., Ltd. was established in December 2005
- Nuowei Optoelectronic Technology Co., Ltd. was established in August 2009.
- In May 2013, the group structure was reorganized, with Cayman Kuangli Optoelectronic Technology Co., Ltd. established as the ultimate parent company.

2014

- In July 2014, Taizhou Kuangli Optoelectronic Technology Co., Ltd. was established.

- In December 2014, Kuangli Optoelectronic Technology Co., Ltd. was listed on the Taiwan Stock Exchange.

2019
-2020

- In May 2019, an investment was made in Alliance Capital Investment INC.
- In September 2019, all shares of Taizhou Kuangli Technology Co., Ltd. were sold.
- In October 2020, an investment was made in Alliance Capital Investment INC.

2021

- In January 2021, a cash capital increase was carried out with the issuance of 4,800,000 common shares.
- In June 2021, the majority stake in ACIM was acquired.
- In June 2021, a private placement of 728,000 common shares was conducted.
- In October 2021, the 100% equity of Kunshan Xinguangtai Optoelectronic Technology Co., Ltd. was sold.
- In October 2021, the 49% equity of Kunshan Kuangli Optoelectronic Technology Co., Ltd. was sold.
- In November 2021, Kuangli Optoelectronic Technology Co., Ltd. officially changed its name to Kuangli Bio-tech Holdings Co., Ltd.


2022 - 2024

- In January 2022, the complete equity of ACIM was acquired.
- In February 2022, a private placement of 11,330,000 Class A Preferred Shares and 6,068,000 common shares was conducted.
- In June 2022, the business classification changed from "Optoelectronics Industry" to "Biotechnology Industry."
- In July 2022, the 51% equity of Kunshan Kuangli Optoelectronic Technology Co., Ltd. was sold.
- In June 2023, Yi dai in Shanghai established a new facility covering an area of 31,000 square meters.
- In 2023, Kuangli Bio-tech Holdings Group launched a new Healthcare integration brand platform called G CLINIC.
- In February 2024, a private placement of 3,830,000 common shares was conducted.
- In March 2025, a private placement of 25,000,000 common shares was conducted.

The current business structure of the Kuangli Bio-tech Group



KUANGLI BIO-TECH
HOLDINGS



Consumer bio-tech and Healthcare bio-tech



KUANGLI BIO-TECH
HOLDINGS

2. Business in China

Shanghai Yi Dai Company Profile



OEM/ODM

R&D Team and Product Design

Service

Standard

GMP Professional Cosmetic Factory

100,000 Level Clean Workshop

Passed ISO 22716 and ISO 14001
certifications

Production

Founded

Founded in 2009

New Factory 31,000m²

20 Production Lines

167 Employees

Address: No. 1, Lane 2255, Yexin Road, Yexie
Town, Songjiang District, Shanghai, China.

Domestic & International Exhibitions Innovation is endless



HONG KONG
2020CIBE



HONG KONG
2019香港亞太展



JAPAN
2018日本展



2019廣州美博會



SHANG HAI
2025CBE美博會



2020CBE美博會



SHANG HAI
2019CBE美博會



SHANG HAI
2024CBE美博會



SHANG HAI
2021CBE美博會



SHANG HAI
2023CBE美博會



SHANG HAI
2018CBE美博會

Product Introduction



面貼膜



塗抹式面膜



潔面



化妝水



精華液



原液



乳液



膏霜



防曬類



氣墊、隔離



洗護類

Business in China-Strategy development



KUANGLI BIO-TECH
HOLDINGS

Development of new products and technologies

Collaborate with raw material suppliers to jointly develop preservative-free (or reduced-preservative) green skincare products using traditional chemical raw materials, such as fermented facial masks.

Development of new customers and cutting-edge customers

Strive for the development of new customers and cutting-edge customers. In 2025, newly developed customers include WIS, Ferneigen, and others.

Installation of Solar Power Systems at the New Plant


Work with the government to install solar power generation systems at the plant, which is expected to reduce electricity costs.

Single-use product line

It is planned to introduce single-dose packaging equipment utilizing BFS aseptic technology, which can effectively preserve product active ingredients, enable precise dosing for each use, and target customer groups such as frequent business travelers.

Yi Dai 2024&2025/1-11 Revenue

Unit: RMB (thousand) yuan




Shanghai Yi Dai -Percentage of Revenue Portfolio




KUANGLI BIO-TECH
HOLDINGS

2025年1~9月營收組合 佔比




■ 化妝水類 ■ 面膜類 ■ 其他膏狀類 ■ 半成品類 ■ 其他類

2024年1~12月營收組合 佔比



■ 化妝水類 ■ 面膜類 ■ 其他膏狀類 ■ 半成品類 ■ 其他類

2023年1~12月營收組合 佔比



■ 化妝水類 ■ 面膜類 ■ 其他膏狀類 ■ 半成品類 ■ 其他類

3. Business in Taiwan

Organizational Chart in Taiwan





SmartHealthcare Integration Platform

G CARE



Global G
Longevity Medicine Integration
Cancer Healthcare Integration
Anti-Aging
Exercise Prescription Platform

G SMART



Telemedicine
Cloud-based Smart Healthcare
Monitoring and Prevention
System
Member Health Management
Service Platform
Digital Health and
Wellness Integration

G FUTURE



Personalized Cell Therapy
Development
Immunocellular Therapy
Development
Stem Cell Secretome
Development
Plasma Product Development

G CLINIC Delivering World-Class Personalized Medical Journeys

5G Advanced Medical Process

GUIDING JOURNEY

智慧細胞療程
Smart cell therapy



PRP增生治療、細胞
因子補充、抗發炎
調理

GOODWILL JOURNEY

營養保健處方箋
Nutrition prescription



客製化營養建議及保
健品規劃

GENIUS JOURNEY

專項儀器 輔助療程
Complementary therapy



熱能量治療(全身/局
部)、血漿置換術TPE
、震波/磁波治 療、
疼痛專科治療

GLAMOUR JOURNEY

運動處方箋
Exercise prescription



運動專業教練訓練方
案、降低肌少症、提
升自體生理機能

GENEROUS JOURNEY

精準醫療
Precision medicine



代謝體健康風險評估
、基因檢測、CTC檢測
、免疫細胞分析、PSA
檢測



診所
療程導入

宸曜綜合健康管理計劃 專業建議運用

全品項導入，自由組合搭配!

全方位健康評估	個性化健康計劃	先進醫療技術	持續健康監測	整合心靈健康
28項 檢測	65種 保健品	38項 療程	G SMART 穿戴裝置	基金會 健身房 工作坊 跨界整合

01

全方位

最新的醫療設備
多項專科檢查

功能檢驗
基因篩檢
非侵入檢測

02

個性化

依評估報告，
量身定制個人健康
管理計劃。

搭配65種保健品。

03

先進技術

精準醫療技術
輔助治療儀器

幹細胞療法
全身熱療
磁震波療法

04

持續照護

可穿戴設備，
實時監控健康數據，在
線醫療諮詢，
及時調整健康計劃。

05

跨界合作

專業心理諮詢
壓力管理課程
健康講座和工作坊，
增強患者健康意識與
自我管理能力。

G CARE : Strengthening Specialized Consultations & Regional Joint Defense System



KUANGLI BIO-TECH
HOLDINGS

Regional Alliance



G CARE : Strengthening Franchise System Support and Guidance Process

Refined SMART Brand Management and Operations



Focused on Partner Operations

G(Glory) CLINIC is focused on the success of partner management, continuously developing the brand and integrating resources to enter new markets.



Strong Brand Management Team

G(Glory) CLINIC has the strongest brand management team, providing the most systematic branding and marketing strategies, including assisting doctors with professional marketing.



Providing Strong Background Support

G(Glory) CLINIC becomes a strong and reliable background support for doctors, allowing them to focus on their own medical specialties.



Systematic Brand Operations

G(Glory) CLINIC provides the most comprehensive systematic branding and operational strategies, helping partners effectively improve their business performance.

Strengthening Standard Operating Procedures for Clinic Opening Support

G CARE : Enhancing Brand Image and Value



KUANGLI BIO-TECH HOLDINGS




Brand Image Gallery Grand Opening
Physician Team Image Building
Community、Online Marketing Promotion



G CARE : Franchise/Alliance Current Status of Locations



KUANGLI BIO-TECH HOLDINGS




G SMART Platform



Mobile System
Client Records




上架中



Cloud
Backend

G SMART Platform -NTU Hospital Collaboration Project

病房設備建置



- 病房病人 vital sign 數據即時回傳護理站-院內獨立 Server(數據保全)
- 護理站/醫師後台 監控
- 病人 數據異常警示
- 緊急事件LINE訊息 即時通知負責護理人員

G FUTURE



Personalized Cell Therapy
Development
Immunocellular Therapy
Development
Stem Cell Secretome
Development
Plasma Product Development

Special Medical Technology Act/Regulations-Commissioned

Development :

Cytokine-Induced Killer Cell therapy for various cancers

Mesenchymal Stem Cell (MSC) Therapy for Spinal Cord Injury (SCI)

Spinal cord injury project - Negotiating with hospitals to accept cases

Shuang Ho Hospital, Ministry of Health and Welfare (Spinal Cord Injury)

Taipei Medical University Hospital (Spinal Cord Injury)

Taipei Municipal Wanfang Hospital (Spinal Cord Injury)

Tamsui Mackay Memorial Hospital (Spinal Cord Injury)


National Taiwan University Hospital (Spinal Cord Injury)

Taiwan Kuangli 2024&2025/1-11 Revenue



Unit: NT\$1,000

Note: Includes monthly fixed rent income




Taiwan Kuangli -Percentage of Revenue Portfolio




KUANGLI BIO-TECH HOLDINGS

2025年1~11月營收組合 佔比



■ 保健產品 ■ 租賃 ■ 品牌商標授權 ■ 行銷 ■ 健康顧問服務 ■ 檢驗服務 ■ 其他

2024年1~12月營收組合 佔比



■ 保健產品 ■ 租賃 ■ 品牌商標授權 ■ 行銷 ■ 健康顧問服務 ■ 檢驗服務 ■ 其他

G MEDICAL MGMT CO., LTD.



宸曜醫務管理顧問股份有限公司

G Medical Management CO., LTD.

G Medical Management is a healthcare management platform built upon the professional foundation of **G CLINIC International Medical**, a subsidiary of Kuangli Bio-tech Holdings Co., Ltd. The company integrates medical expertise, health management, and brand operations to support sustainable development within the healthcare industry.

G Medical Management oversees the **G CLINIC** health supplement brand, developing evidence-based products derived from clinical insight and strict quality standards. In addition, the company provides structured support for medical clinic operations, including brand development and operational optimization, helping healthcare institutions enhance efficiency, professional value, and long-term competitiveness.



We are a company focused on **medical aesthetics, premium health care, clean nurturing, and technological innovation**, guided by the philosophy of “**Medical Expertise × Biotechnological R&D × Aesthetic Branding.**”

By integrating **G CLINIC experience and research capabilities**, we establish a **Clinic-to-Care physician collaboration model**, delivering holistic health solutions that connect **external care with internal wellness** for a refined, science-driven lifestyle.

GLOREAU BIO-TECH CO., LTD.



中時新聞網 真道理性 真愛台灣

光麗旗下新品牌「蔻芮安」亮相國際美容盛會Cosmoprof Asia

21:36 2025/11/12 | 中時新聞網 陳泳濤 | 點讚 | 設定作者



Brand Philosophy:
“Let light coexist with the skin — natural radiance is the most beautiful foundation.”

本次參展產品以「恆光修護」配力刀：專人積雪早復
合植萃、透明質酸×聚谷氨酸複合補水系統與多重胜肽。

主打保濕、舒緩與光澤；現場同步展示「5+1恆光保養儀式」，自潔顏、精粹水、精華至精粹乳、精粹
霜，搭配每週2-3次面膜保養，協助肌膚維持柔潤穩定與自然光顏。



GLOREAU BIO-TECH CO., LTD.

 KUANGLI BIO-TECH
HOLDINGS



Gloreau International focuses on the group's overall market strategy and sales deployment.

By vertically integrating diverse resources across biotechnology, beauty, preventive medicine, and health management, we build a complete and highly competitive industry ecosystem.

With flexible and innovative business models combined with precise and effective market strategies, Chanli International empowers its partners to enter the market rapidly, amplify brand value, and achieve sustainable revenue growth.

AI BIO-TECH CO., LTD.



Ai Bio-tech co.,Ltd., in close collaboration with group-affiliated **G CLINIC International Medical System**, leverages integrated medical and clinical resources to advance innovation in **AI-driven healthcare and AI biotechnology**.

Centered on cutting-edge **artificial intelligence algorithms**, Ai Bio-tech focuses on the development of intelligent medical systems, **biomedical image recognition technologies**, and the **design, integration, and commercialization of medical and biotechnology equipment**. Through the convergence of AI, clinical expertise, and biotechnology, the company is committed to delivering scalable, precise, and next-generation solutions for modern healthcare and life science industries.


4. Financial Information

Financial results for the first three
quarters of 2025(Consolidated)

Consolidated Revenue , Gross Profit & Net Income



KUANGLI BIO-TECH
HOLDINGS



Key Financial Ratios



NT\$ Thousand	2023.12.31	2024.12.31	2025.09.30
Current Ratio	107.98%	80.92%	155.21%
Debt Ratio	46.52%	49.47%	46.88%
Debt-To-Equity Ratio	86.99%	97.88%	88.26%
Net Asset Value	8.14	6.35	6.27
EPS (The merger benefits are for one quarter)	(1.82)	(2.52)	(1.44)

Note: As of September 30, 2025, the company's shareholders' equity is NT\$610,358 thousand; the common shares total 97,399 thousand shares, with a net value per share of NT\$6.27.

Thank You
Q&A